{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:15:14Z","timestamp":1794244514540,"version":"4.9.0"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.neubiorev.2024.105691","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T01:55:20Z","timestamp":1715392520000},"page":"105691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["New trends of drug abuse in custodial settings: A systematic review on the misuse of over-the-counter drugs, prescription-only-medications, and new psychoactive substances"],"prefix":"10.1016","volume":"162","author":[{"given":"Stefania","family":"Chiappini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Miuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Stigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Stefanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Carullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"d\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Cavallotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Pettorruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Di Petta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Martin","family":"Corkery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Guirguis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline L.","family":"Stair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seena","family":"Fazel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neubiorev.2024.105691_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/dta.2965","article-title":"Shape matters: The application of activity-based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons","volume":"13","author":"Antonides","year":"2021","journal-title":"Drug Test. Anal."},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40263-024-01064-5","article-title":"Trends in pregabalin use and prescribing patterns in the adult population: a 10-Year Pharmacoepidemiologic Study","volume":"38","author":"Benassayag Kaduri","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neubiorev.2024.105691_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2016.11.032","article-title":"Prescription opioid abuse in prison settings: a systematic review of prevalence, practice and treatment responses","volume":"Vol. 171","author":"Bi-Mohammed","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib4","doi-asserted-by":"crossref","DOI":"10.2196\/17073","article-title":"Online conversation monitoring to understand the opioid epidemic: epidemiological surveillance study","volume":"6","author":"Black","year":"2020","journal-title":"JMIR Public Health Surveill."},{"key":"10.1016\/j.neubiorev.2024.105691_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2019.105972","article-title":"Prescription opioid misuse among adolescents and emerging adults in the United States: a scoping review","volume":"132","author":"Bonar","year":"2020","journal-title":"Prev. Med."},{"key":"10.1016\/j.neubiorev.2024.105691_bib6","unstructured":"Bonds, C., & Hudson, S. (2015). North West \u201cThrough the Gate Substance Misuse Services\u201d Drug Testing Project Client Research Laboratory National Offender Management Service LGC Limited Newmarket Road Fordham Cambs CB7 5WW Main Title Arial size 12 Secondary Title Arial size 10."},{"key":"10.1016\/j.neubiorev.2024.105691_bib7","first-page":"137","article-title":"Prevalence and risk factors for opioid related mortality among probation clients in an American city","author":"Boulger","year":"2022","journal-title":"J. Subst. Abus. Treat."},{"issue":"5","key":"10.1016\/j.neubiorev.2024.105691_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.18773\/austprescr.2015.055","article-title":"Management of benzodiazepine misuse and dependence","volume":"38","author":"Brett","year":"2015","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.neubiorev.2024.105691_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugpo.2019.05.018","article-title":"Fentanyl behind bars: The implications of synthetic opiates for prisoners and correctional officers","volume":"71","author":"Bucerius","year":"2019","journal-title":"Int. J. Drug Policy"},{"issue":"Issue 3","key":"10.1016\/j.neubiorev.2024.105691_bib10","article-title":"A theoretical framework for goal-directed care within the prison system","volume":"Vol. 13","author":"Bulten","year":"2008","journal-title":"Ment. Health Rev. J."},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib11","article-title":"Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment","volume":"16","author":"Butler","year":"2015","journal-title":"Pain. Med. (U. S.)"},{"key":"10.1016\/j.neubiorev.2024.105691_bib12","first-page":"324","article-title":"A case report on fatal intoxication by tapentadol: study of distribution and metabolism","author":"Carelli","year":"2021","journal-title":"Forensic Sci. Int."},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/pmt-2019-0052","article-title":"Abuse-deterrent opioid analgesics: a guide for clinicians","volume":"10","author":"Carinci","year":"2020","journal-title":"Pain. Manag."},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5409\/wjcp.v5.i1.16","article-title":"Synthetic cannabinoids 2015: an update for pediatricians in clinical practice","volume":"5","author":"Castellanos","year":"2016","journal-title":"World J. Clin. Pediatr."},{"key":"10.1016\/j.neubiorev.2024.105691_bib15","first-page":"305","article-title":"Analysis of synthetic cannabinoids on paper before and after processing for latent print using DFO and ninhydrin","author":"Caterino","year":"2019","journal-title":"Forensic Sci. Int."},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib16","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1038\/s41467-023-40637-8","article-title":"Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study","volume":"14","author":"Chan","year":"2023","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.neubiorev.2024.105691_bib17","article-title":"Association between prescription of major psychotropic medications and violent reoffending after prison release","volume":"316","author":"Chang","year":"2016","journal-title":"JAMA\u00a0J. Am. Med. Assoc."},{"issue":"Issue 6","key":"10.1016\/j.neubiorev.2024.105691_bib18","article-title":"New psychoactive substances and suicidality: a systematic review of the current literature","volume":"Vol. 57","author":"Chiappini","year":"2021","journal-title":"Med. (Lith. )"},{"issue":"Issue 2","key":"10.1016\/j.neubiorev.2024.105691_bib19","article-title":"Misuse of anticholinergic medications: a systematic review","volume":"Vol. 10","author":"Chiappini","year":"2022","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.neubiorev.2024.105691_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s40263-016-0359-y","article-title":"A Decade of Gabapentinoid Misuse: An Analysis of the European medicines agency\u2019s \u2018suspected adverse drug reactions\u2019 database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neubiorev.2024.105691_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JCP.0000000000000814","article-title":"Is there a potential of misuse for quetiapine?: literature review and analysis of the European Medicines Agency\/European Medicines Agency Adverse Drug Reactions\u2019 database","volume":"38","author":"Chiappini","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Issue 10","key":"10.1016\/j.neubiorev.2024.105691_bib22","article-title":"What about \u201cpharming\u201d? Issues regarding the misuse of prescription and over-the-counter drugs","volume":"Vol. 10","author":"Chiappini","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.neubiorev.2024.105691_bib23","doi-asserted-by":"crossref","DOI":"10.24165\/jns.10014.17","article-title":"The comparison of socio-demographic and clinical variables between inmates using gabapentin for medicinal purposes and those abusing the drug","author":"Cicekci","year":"2017","journal-title":"J. Neurol. Sci. (Turk. )"},{"key":"10.1016\/j.neubiorev.2024.105691_bib24","first-page":"11","article-title":"Novel psychoactive substances in custodial settings: a mixed method investigation on the experiences of people in prison and professionals working with them","author":"Corazza","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2024.105691_bib25","article-title":"Assessment of the abuse of tapentadol immediate release: the first 24 months","volume":"8","author":"Dart","year":"2012","journal-title":"J. Opioid Manag."},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib26","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/bcp.14791","article-title":"Measuring prescription opioid misuse and its consequences","volume":"87","author":"Dart","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2024.105691_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.neubiorev.2024.105691_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/jat\/bkz105","article-title":"An insight into gabapentin and pregabalin in scottish prisoners","volume":"44","author":"Deeb","year":"2020","journal-title":"J. Anal. Toxicol."},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40352-021-00162-6","article-title":"A systematic review of post-release programs for women exiting prison with substance-use disorders: assessing current programs and weighing the evidence","volume":"10","author":"Edwards","year":"2022","journal-title":"Health Justice"},{"key":"10.1016\/j.neubiorev.2024.105691_bib30","unstructured":"EMCDDA (2018). Results from an EMCDDA Trendspotter Study New Psychoactive Substances in Prison."},{"key":"10.1016\/j.neubiorev.2024.105691_bib31","unstructured":"EMCDDA (2020). European Drug Report 2020: Trends and Developments [Internet]. Luxembourg; 2020. \u3008https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/13236\/TDAT20001ENN_web.pdf\u3009."},{"key":"10.1016\/j.neubiorev.2024.105691_bib32","unstructured":"EMCDDA (2022). EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances."},{"key":"10.1016\/j.neubiorev.2024.105691_bib33","unstructured":"EMCDDA (2023). European Drug Report 2023: Trends and Developments, \u3008https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2023_en\u3009."},{"key":"10.1016\/j.neubiorev.2024.105691_bib34","unstructured":"European Union (2021). Risk assessment for violence in prisons. \u3008https:\/\/home-affairs.ec.europa.eu\/system\/files\/2021-04\/ran_cons_overv_pap_risk_assessment_in_prison_20210210_en.pdf\u3009."},{"issue":"S2","key":"10.1016\/j.neubiorev.2024.105691_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.1833","article-title":"Gabapentinoid pharmacology in the context of emerging misuse liability","volume":"61","author":"Evoy","year":"2021","journal-title":"J. Clin. Pharmacol."},{"issue":"Issue 9769","key":"10.1016\/j.neubiorev.2024.105691_bib36","article-title":"The health of prisoners","volume":"Vol. 377","author":"Fazel","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.neubiorev.2024.105691_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/S2215-0366(17)30430-3","article-title":"Suicide in prisons: an international study of prevalence and contributory factors","volume":"4","author":"Fazel","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1192\/bjp.2018.145","article-title":"Risk factors for interpersonal violence: an umbrella review of meta-analyses","volume":"213","author":"Fazel","year":"2018","journal-title":"Br J. Psychiatry."},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/0004563216651646","article-title":"Analysis of legal high materials by ultra-performance liquid chromatography with time of flight mass spectrometry as part of a toxicology vigilance system: what are the most popular novel psychoactive substances in the UK","volume":"54","author":"Ford","year":"2017","journal-title":"Ann. Clin. Biochem."},{"issue":"6","key":"10.1016\/j.neubiorev.2024.105691_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/0004563218767462","article-title":"Analytical evidence to show letters impregnated with novel psychoactive substances are a means of getting drugs to inmates within the UK prison service","volume":"55","author":"Ford","year":"2018","journal-title":"Ann. Clin. Biochem."},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/jat\/31.4.220","article-title":"Formation of scopolamine from N-butyl-scopolammonium bromide in cigarettes","volume":"31","author":"Frascht","year":"2007","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neubiorev.2024.105691_bib42","article-title":"Analysis of illicit drugs in purchased and seized electronic cigarette liquids from the United Kingdom 2014\u20132021","author":"Frinculescu","year":"2022","journal-title":"Drug Test. Anal."},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.lfs.2013.07.023","article-title":"Bath salts and synthetic cathinones: an emerging designer drug phenomenon","volume":"97","author":"German","year":"2014","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.neubiorev.2024.105691_bib44","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/dta.3351","article-title":"Detection of AP-237 and synthetic cannabinoids on an infused letter sent to a German prisoner","volume":"14","author":"Giorgetti","year":"2022","journal-title":"Drug Test. Anal."},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.18176\/resp.00052","article-title":"Mental and behavioral disorders in the prison context","volume":"24","author":"G\u00f3mez-Figueroa","year":"2022","journal-title":"Rev. Esp. Sanid. Penit."},{"key":"10.1016\/j.neubiorev.2024.105691_bib46","unstructured":"GOV.UK. (2016). Psychoactive Substances Act 2016 - GOV.UK. \u3008http:\/\/www.legislation.gov.uk\/ukpga\/2016\/2\/crossheading\/psychoactive-substances\/enacted\u3009."},{"issue":"12","key":"10.1016\/j.neubiorev.2024.105691_bib47","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40264-020-00985-6","article-title":"Current evidence on abuse and misuse of Gabapentinoids","volume":"43","author":"H\u00e4gg","year":"2020","journal-title":"Drug Saf."},{"issue":"11","key":"10.1016\/j.neubiorev.2024.105691_bib48","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s12264-022-00872-3","article-title":"Unique pharmacology, brain dysfunction, and therapeutic advancements for fentanyl misuse and abuse","volume":"38","author":"Han","year":"2022","journal-title":"Neurosci. Bull."},{"issue":"Issue 8","key":"10.1016\/j.neubiorev.2024.105691_bib49","article-title":"DSM-5 criteria for substance use disorders: Recommendations and rationale","volume":"Vol. 170","author":"Hasin","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232038","article-title":"Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: experiences from the STRIDA project","volume":"15","author":"Helander","year":"2020","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.neubiorev.2024.105691_bib51","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","article-title":"Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings","volume":"108","author":"Hermanns-Clausen","year":"2013","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.neubiorev.2024.105691_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/1078345813486448","article-title":"Bupropion diversion and misuse in the correctional facility","volume":"19","author":"Hilliard","year":"2013","journal-title":"J. Correct. Health Care"},{"key":"10.1016\/j.neubiorev.2024.105691_bib53","unstructured":"HM Inspectorate of Prisons for England and Wales., Clarke, Peter., & Hardwick, Nick. (2016). HM Chief Inspector of Prisons for England and Wales annual report 2015-16. \u3008https:\/\/www.justiceinspectorates.gov.uk\/hmiprisons\/wp-content\/uploads\/sites\/4\/2016\/07\/HMIP-AR_2015-16_web.pdf\u3009."},{"key":"10.1016\/j.neubiorev.2024.105691_bib54","unstructured":"HM Inspectorate of Prisons for England and Wales., Clarke, Peter., & Hardwick, Nick (Great Britain). (2017). HM Chief Inspector of Prisons for England and Wales annual report 2016-17. \u3008https:\/\/www.justiceinspectorates.gov.uk\/hmiprisons\/wp-content\/uploads\/sites\/4\/2017\/07\/HMIP-AR_2016-17_CONTENT_201017_WEB.pdf\u3009."},{"key":"10.1016\/j.neubiorev.2024.105691_bib55","article-title":"Gabapentinoids: the rise of a new misuse epidemics","volume":"305","author":"Hofmann","year":"2021","journal-title":"Psychiatry Res. Nov."},{"issue":"3","key":"10.1016\/j.neubiorev.2024.105691_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/jat\/bkz092","article-title":"Case Report: synthetic cannabinoid deaths in State of Florida Prisoners","volume":"44","author":"Hvozdovich","year":"2020","journal-title":"J. Anal. Toxicol."},{"issue":"3","key":"10.1016\/j.neubiorev.2024.105691_bib57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40261-021-01009-6","article-title":"Prevalence of and factors associated with gabapentinoid use and misuse among texas medicaid recipients","volume":"41","author":"Ibiloye","year":"2021","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/j.1526-4637.2006.00255.x","article-title":"Mechanisms of prescription drug diversion among drug-Involved club- and street-based populations","volume":"8","author":"Inciardi","year":"2007","journal-title":"Pain. Med."},{"issue":"7","key":"10.1016\/j.neubiorev.2024.105691_bib59","doi-asserted-by":"crossref","DOI":"10.3109\/10826084.2014.880178","article-title":"Smoking crushed hyoscine\/scopolamine tablets as drug abuse","volume":"49","author":"Jalali","year":"2014","journal-title":"Subst. Use Misuse"},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12954-021-00480-w","article-title":"\"My first 48\u2009h out\": drug users' perspectives on challenges and strategies upon release from prison","volume":"18","author":"Jamin","year":"2021","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.neubiorev.2024.105691_bib61","unstructured":"Kastelic, A., Pont, J., & St\u00f6ver, H. 1956-. (2012). Opioid substitution treatment in custodial settings a practical guide."},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40352-018-0063-8","article-title":"Systematic review of qualitative evaluations of reentry programs addressing problematic drug use and mental health disorders amongst people transitioning from prison to communities","volume":"6","author":"Kendall","year":"2018","journal-title":"Health Justice"},{"key":"10.1016\/j.neubiorev.2024.105691_bib63","first-page":"314","article-title":"The synthetic cannabinoid 5F-MDMB-PICA: A case series","author":"Kleis","year":"2020","journal-title":"Forensic Sci. Int."},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/dta.2935","article-title":"The next generation of synthetic cannabinoids: Detection, activity, and potential toxicity of pent-4en and but-3en analogues including MDMB-4en-PINACA","volume":"13","author":"Krotulski","year":"2021","journal-title":"Drug Test. Anal."},{"issue":"Issue 3","key":"10.1016\/j.neubiorev.2024.105691_bib65","article-title":"\u201cPharming\u201d: The abuse of prescription and over-the-counter drugs in teens","volume":"Vol. 19","author":"Levine","year":"2007","journal-title":"Curr. Opin. Pediatr."},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib66","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1108\/17449201211277192","article-title":"Barriers to implementing throughcare for problematic drug users in European prisons","volume":"8","author":"MacDonald","year":"2012","journal-title":"Int. J. Prison. Health"},{"issue":"3","key":"10.1016\/j.neubiorev.2024.105691_bib67","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1037\/ser0000102","article-title":"Violence risk assessment and psychological treatment in correctional and forensic settings: advances in research and practice","volume":"13","author":"Magaletta","year":"2016","journal-title":"Psychol. Serv."},{"issue":"6","key":"10.1016\/j.neubiorev.2024.105691_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067366","article-title":"Developing best practice principles for the provision of programs and services to people transitioning from custody to the community: study protocol for a modified Delphi consensus exercise","volume":"13","author":"Majeed","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib69","doi-asserted-by":"crossref","DOI":"10.1017\/S1092852920001479","article-title":"Substance-related exogenous psychosis: a postmodern syndrome","volume":"26","author":"Martinotti","year":"2021","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neubiorev.2024.105691_bib70","series-title":"In Substance Use and Misuse","article-title":"New Psychoactive Substances and Violence within a UK Prison Setting","author":"Mason","year":"2022"},{"key":"10.1016\/j.neubiorev.2024.105691_bib71","first-page":"92","article-title":"Understanding overdose incidents in Canadian federal custody","author":"McKendy","year":"2021","journal-title":"Int. J. Drug Policy"},{"issue":"6","key":"10.1016\/j.neubiorev.2024.105691_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/dta.2565","article-title":"Ion mobility spectrometry as a fast screening tool for synthetic cannabinoids to uncover drug trafficking in jail via herbal mixtures, paper, food, and cosmetics","volume":"11","author":"Metternich","year":"2018","journal-title":"Drug Test. Anal."},{"issue":"Issue 2","key":"10.1016\/j.neubiorev.2024.105691_bib73","article-title":"Poisoning due to MDMB-CHMICA, a synthetic cannabinoid receptor agonist","volume":"Vol. 55","author":"Meyyappan","year":"2017","journal-title":"Clin. Toxicol."},{"issue":"Issue 7","key":"10.1016\/j.neubiorev.2024.105691_bib74","article-title":"Sales and advertising channels of new psychoactive substances (NPS): Internet, social networks, and smartphone apps","volume":"Vol. 8","author":"Miliano","year":"2018","journal-title":"Brain Sci."},{"issue":"10","key":"10.1016\/j.neubiorev.2024.105691_bib75","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2018.17101112","article-title":"Medications for alcohol and opioid use disorders and risk of suicidal behavior, accidental overdoses, and crime","volume":"175","author":"Molero","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2024.105691_bib76","doi-asserted-by":"crossref","DOI":"10.1080\/17470919.2023.2242096","article-title":"To bridge or not to bridge: moral judgement in cocaine use disorders, a case-control study on human morality","author":"Mosca","year":"2023","journal-title":"Soc. Neurosci."},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib77","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bpa.2017.05.004","article-title":"Opioids, respiratory depression, and sleep-disordered breathing","volume":"31","author":"Nagappa","year":"2017","journal-title":"Best Pract. Res. Clin. Anaesthesiol."},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251006","article-title":"Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014","volume":"16","author":"Neicun","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.neubiorev.2024.105691_bib79","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.disamonth.2014.01.001","article-title":"Emerging drugs of abuse","volume":"60","author":"Nelson","year":"2014","journal-title":"Dis. Mon."},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/dta.3002","article-title":"A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: comparing prison and general populations","volume":"13","author":"Norman","year":"2021","journal-title":"Drug Test. Anal."},{"issue":"3","key":"10.1016\/j.neubiorev.2024.105691_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/dta.2945","article-title":"Large-scale evaluation of ion mobility spectrometry for the rapid detection of synthetic cannabinoid receptor agonists in infused papers in prisons","volume":"13","author":"Norman","year":"2021","journal-title":"Drug Test. Anal."},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/dta.2767","article-title":"Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market","volume":"12","author":"Norman","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neubiorev.2024.105691_bib83","unstructured":"Ombudsman, P. (2015). Prison and Probations Ombudsman Learning Lessons Bulletin - Fatal incident investigations. http:\/\/www.drugscope.org.uk\/."},{"key":"10.1016\/j.neubiorev.2024.105691_bib84","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"Vol. 372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.neubiorev.2024.105691_bib85","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.08.028","article-title":"Self-reported use of novel psychoactive substances in a US nationally representative survey: prevalence, correlates, and a call for new survey methods to prevent underreporting","volume":"156","author":"Palamar","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib86","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hup.2312","article-title":"\"Spiceophrenia\": a systematic overview of \"spice\"-related psychopathological issues and a case report","volume":"28","author":"Papanti","year":"2013","journal-title":"Hum Psychopharmacol."},{"issue":"9","key":"10.1016\/j.neubiorev.2024.105691_bib87","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/dta.3333","article-title":"Identification of the synthetic cannabinoid-type new psychoactive substance, CH-PIACA, in seized material","volume":"14","author":"Pasin","year":"2022","journal-title":"Drug Test. Anal."},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib88","doi-asserted-by":"crossref","DOI":"10.1093\/jat\/30.4.267","article-title":"Comparison of the various opiate alkaloid contaminants and their metabolites found in illicit heroin with 6-monoacetyl morphine as indicators of heroin ingestion","volume":"30","author":"Paterson","year":"2006","journal-title":"J. Anal. Toxicol."},{"issue":"9","key":"10.1016\/j.neubiorev.2024.105691_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/dta.3101","article-title":"Air monitoring for synthetic cannabinoids in a UK prison: Application of personal air sampling and fixed sequential sampling with thermal desorption two-dimensional gas chromatography coupled to time-of-flight mass spectrometry","volume":"13","author":"Paul","year":"2021","journal-title":"Drug Test. Anal."},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2010.06.012","article-title":"Evaluation of drugs of abuse use and trends in a prison through wastewater analysis","volume":"37","author":"Postigo","year":"2011","journal-title":"Environ. Int."},{"issue":"11","key":"10.1016\/j.neubiorev.2024.105691_bib91","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.2174\/1570159X19666210412101929","article-title":"Synthetic cannabinoids and cathinones cardiotoxicity: facts and perspectives","volume":"19","author":"Radaelli","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neubiorev.2024.105691_bib92","first-page":"61","article-title":"Factors affecting drug use during incarceration: a cross-sectional study of opioid-dependent persons from India","author":"Rao","year":"2016","journal-title":"J. Subst. Abus. Treat."},{"issue":"3","key":"10.1016\/j.neubiorev.2024.105691_bib93","doi-asserted-by":"crossref","DOI":"10.1080\/10550490490460300","article-title":"Gabapentin abuse in inmates with prior history of cocaine dependence","volume":"13","author":"Reccoppa","year":"2004","journal-title":"Am. J. Addict."},{"issue":"Issue 4","key":"10.1016\/j.neubiorev.2024.105691_bib94","article-title":"Additional evidence of the abuse potential of bupropion","volume":"Vol. 33","author":"Reeves","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.neubiorev.2024.105691_bib95","doi-asserted-by":"crossref","DOI":"10.1111\/add.15468","article-title":"Drug-related deaths associated with vaping product use in the United Kingdom","volume":"116","author":"Roberts","year":"2021","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib96","doi-asserted-by":"crossref","DOI":"10.1007\/s11419-021-00586-7","article-title":"Synthetic cannabinoid receptor agonists profile in infused papers seized in Brazilian prisons","volume":"40","author":"Rodrigues","year":"2022","journal-title":"Forensic Toxicol."},{"issue":"Issue 6","key":"10.1016\/j.neubiorev.2024.105691_bib97","article-title":"Four analytically confirmed cases of use of third-generation synthetic cannabinoid receptor agonists incorporating an adamantyl group","volume":"Vol. 54","author":"Rook","year":"2016","journal-title":"Clin. Toxicol."},{"issue":"Issue 6","key":"10.1016\/j.neubiorev.2024.105691_bib98","article-title":"Misuse and abuse of pregabalin and gabapentin: cause for concern","volume":"Vol. 28","author":"Schifano","year":"2014","journal-title":"? CNS Drugs"},{"issue":"Issue 4","key":"10.1016\/j.neubiorev.2024.105691_bib99","article-title":"Abuse of prescription drugs in the context of novel psychoactive substances (NPS): a systematic review","volume":"Vol. 8","author":"Schifano","year":"2018","journal-title":"Brain Sci."},{"issue":"MAR","key":"10.1016\/j.neubiorev.2024.105691_bib100","article-title":"Is there a potential of misuse for venlafaxine and bupropion","volume":"9","author":"Schifano","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"Issue 1","key":"10.1016\/j.neubiorev.2024.105691_bib101","article-title":"New\/emerging psychoactive substances and associated psychopathological consequences","volume":"Vol. 51","author":"Schifano","year":"2021","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20174","article-title":"Novel psychoactive substances of interest for psychiatry","volume":"14","author":"Schifano","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.neubiorev.2024.105691_bib103","article-title":"NPS: medical consequences associated with their intake","volume":"Vol. 32","author":"Schifano","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.neubiorev.2024.105691_bib104","article-title":"Synthetic cannabinoid receptor agonists in postmortem casework in Scotland","author":"Seywright","year":"2022","journal-title":"J. Anal. Toxicol."},{"issue":"3","key":"10.1016\/j.neubiorev.2024.105691_bib105","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2606","article-title":"The risk of violence associated with novel psychoactive substance misuse in patients presenting to acute mental health services","volume":"32","author":"Shafi","year":"2017","journal-title":"Hum Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2024.105691_bib106","doi-asserted-by":"crossref","unstructured":"Shamseer L., Moher D., Clarke M., Ghersi D., Liberati A., Petticrew M., Shekelle P., Stewart L., & the PRISMA-P Group. (2015). Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. BMJ (Online), 349.","DOI":"10.1136\/bmj.g7647"},{"issue":"8","key":"10.1016\/j.neubiorev.2024.105691_bib107","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.3390\/ijerph19084869","article-title":"An update on the implications of new psychoactive substances in public health","volume":"19","author":"Sim\u00e3o","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib108","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00213-013-3188-4","article-title":"Spicing things up: synthetic cannabinoids","volume":"228","author":"Spaderna","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib109","doi-asserted-by":"crossref","DOI":"10.1515\/ijamh-2018-0179","article-title":"Trends and risk factors of adolescent opioid abuse\/misuse: understanding the opioid epidemic among adolescents","volume":"33","author":"Spencer","year":"2020","journal-title":"Int. J. Adolesc. Med. Health"},{"issue":"13","key":"10.1016\/j.neubiorev.2024.105691_bib110","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.131534","article-title":"Bupropion abuse and overdose","volume":"186","author":"Stall","year":"2014","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.neubiorev.2024.105691_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103803","article-title":"Medication for opioid use disorder treatment continuity post-release from jail: a qualitative study with community-based treatment providers","volume":"110","author":"Stopka","year":"2022","journal-title":"Int. J. Drug Policy"},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib112","doi-asserted-by":"crossref","DOI":"10.1007\/s00414-021-02583-2","article-title":"Scopolamine fatal outcome in an inmate after buscopan\u00ae smoking","volume":"135","author":"Strano-Rossi","year":"2021","journal-title":"Int. J. Leg. Med."},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib113","doi-asserted-by":"crossref","DOI":"10.31887\/DCNS.2015.17.2\/btolliver","article-title":"Assessment and treatment of mood disorders in the context of substance abuse","volume":"17","author":"Tolliver","year":"2015","journal-title":"Dialog-. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib114","doi-asserted-by":"crossref","DOI":"10.1080\/17449200902880482","article-title":"Exploring prison buprenorphine misuse in the United Kingdom: A qualitative study of former prisoners","volume":"5","author":"Tompkins","year":"2009","journal-title":"Int. J. Prison. Health"},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bja.2020.05.017","article-title":"Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland","volume":"125","author":"Torrance","year":"2020","journal-title":"Br. J. Anaesth."},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib116","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp1505328","article-title":"Synthetic cannabinoid-related illnesses and deaths","volume":"373","author":"Trecki","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neubiorev.2024.105691_bib117","unstructured":"UNODC. (2021). WORLD DRUG REPORT 2020 (SET OF 6 BOOKLETS). UNITED NATIONS."},{"key":"10.1016\/j.neubiorev.2024.105691_bib118","unstructured":"UNODC (2019). World Drug Report 2018. Available at: https:\/\/www.unodc.org\/wdr2018\/ [Accessed 02 November 2018]."},{"issue":"Issue 8","key":"10.1016\/j.neubiorev.2024.105691_bib119","article-title":"NPS detection in prison: a systematic literature review of use, drug form, and analytical approaches","volume":"Vol. 14","author":"Vaccaro","year":"2022","journal-title":"Drug Test. Anal."},{"issue":"5","key":"10.1016\/j.neubiorev.2024.105691_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.scijus.2014.06.006","article-title":"Monitoring substance use in prisons: assessing the potential value of wastewater analysis","volume":"54","author":"van Dyken","year":"2014","journal-title":"Sci. Justice"},{"issue":"2","key":"10.1016\/j.neubiorev.2024.105691_bib121","doi-asserted-by":"crossref","DOI":"10.1111\/dar.12156","article-title":"Challenges and opportunities in using wastewater analysis to measure drug use in a small prison facility","volume":"35","author":"Van Dyken","year":"2016","journal-title":"Drug Alcohol Rev."},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib122","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1108\/IJPH-01-2019-0008","article-title":"Linkage and continuity of care after release from prison: an evaluation of central registration points for drug users in Belgium","volume":"17","author":"Vandevelde","year":"2020","journal-title":"Int. J. Prison. Health"},{"issue":"3","key":"10.1016\/j.neubiorev.2024.105691_bib123","article-title":"Cognition and addiction","volume":"21","author":"Verdejo-Garcia","year":"2019","journal-title":"Dialog.\u00a0Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib124","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12888-017-1490-0","article-title":"Protocol for the management of psychiatric patients with psychomotor agitation","volume":"17","author":"Vieta","year":"2017","journal-title":"BMC Psychiatry"},{"issue":"9","key":"10.1016\/j.neubiorev.2024.105691_bib125","article-title":"Evaluation of abuse and route of administration of extended-release tapentadol among treatment-seeking individuals, as captured by the addiction severity index\u2013multimedia version (ASI-MV","volume":"21","author":"Vosburg","year":"2020","journal-title":"Pain. Med. (U. S. )"},{"key":"10.1016\/j.neubiorev.2024.105691_bib126","article-title":"Does in-prison physical and mental health impact recidivism","volume":"11","author":"Wallace","year":"2020","journal-title":"SSM Popul. Health"},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib127","doi-asserted-by":"crossref","DOI":"10.1093\/jat\/28.1.67","article-title":"A2 (N-Benzylpiperazine) a new drug of abuse in Sweden","volume":"28","author":"Wikstr\u00f6m","year":"2004","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neubiorev.2024.105691_bib128","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.drugalcdep.2012.12.011","article-title":"Synthetic Cannabis: A Comparison of Patterns of Use and Effect Profile with Natural Cannabis in a Large Global Sample","volume":"131","author":"Winstock","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.neubiorev.2024.105691_bib129","doi-asserted-by":"crossref","DOI":"10.1080\/10550887.2011.642757","article-title":"The emerging buprenorphine epidemic in the United States","volume":"31","author":"Wish","year":"2012","journal-title":"J. Addict. Dis."},{"issue":"4","key":"10.1016\/j.neubiorev.2024.105691_bib130","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1089\/can.2020.0161","article-title":"Synthetic cannabinoid-related deaths in England, 2012-2019","volume":"7","author":"Yoganathan","year":"2022","journal-title":"Cannabis Cannabinoid Res."}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014976342400160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014976342400160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:36:23Z","timestamp":1732732583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014976342400160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":130,"alternative-id":["S014976342400160X"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2024.105691","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New trends of drug abuse in custodial settings: A systematic review on the misuse of over-the-counter drugs, prescription-only-medications, and new psychoactive substances","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2024.105691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105691"}}